Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Open-Label Dose-Escalation Study of MEDI-575 in Advanced Solid Tumors
jRCT2080221095Phase 1
- Sponsor
- AstraZeneca
- Start
- May 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Tovetumab in Non-hematologic malignancy and hepatocellular carcinoma (HCC), sponsored by AstraZeneca. Primary endpoints: Safety and tolerability of ascending doses of MEDI-575 and Pharmacokinetics of MEDI-575.
02
Drugs
Tovetumab
03
Conditions
Non-hematologic malignancyhepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on jRCT2080221095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221095.